




RealRate

PHARMACEUTICAL 2021

Serina Therapeutics Inc
Rank 375 of 394



The relative strengths and weaknesses of Serina Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Serina Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 11% points. The greatest weakness of Serina Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 175% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 201% points below the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	2,283	Assets	3,925
Cost of Goods Sold	158	Liabilities	9,321
Intangible Assets	1,592	Expenses	12,389
Liabilities, Current	5,357	Revenues	1,868
Liabilities, Non-Current	64	Stockholders Equity	-5,396
Other Assets	50	Net Income	-10,976
Other Compr. Net Income	74	Comprehensive Net Income	-10,939
Other Expenses	-150	BaseVar	14,016
Other Liabilities	3,900	ECR before LimitedLiability	-343%
Other Net Income	-455	Economic Capital Ratio	55%
Other Revenues	1,868		
Property and Equipment	0		
Research and Development	4,978		
Selling, General and Administrative Expense	7,403		